Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

BACKGROUND: This study aimed to analyze the cost-effectiveness of crizotinib versus ceritinib or alectinib as first-line-targeted drug therapy for anaplastic lymphoma kinase-positive advanced non-small cell lung cancer in China. METHODS: The Markov model was used to simulate the medical cost and qua...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Maobai, Zhang, Longfeng, Huang, Qishu, Li, Na, Zheng, Bin, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818540/
https://www.ncbi.nlm.nih.gov/pubmed/31749634
http://dx.doi.org/10.2147/CMAR.S223441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818540/
https://www.ncbi.nlm.nih.gov/pubmed/31749634
http://dx.doi.org/10.2147/CMAR.S223441

Ejemplares similares